On Friday, Following U.S. Stocks were among the “Top Gainers”: Rock-Tenn Company (NYSE:RKT), Teradyne Inc. (NYSE:TER), General Growth Properties, Inc (NYSE:GGP), Biogen Idec Inc. (NASDAQ:BIIB)
Rock-Tenn Company (NYSE:RKT), with shares inclined 1.50%, closed at $66.12.
Teradyne Inc. (NYSE:TER), with shares jumped 1.46%, settled at $19.46.
General Growth Properties, Inc (NYSE:GGP), with shares climbed 1.44%, and closed at $29.65.
Biogen Idec Inc. (NASDAQ:BIIB), surged 1.40%, and closed at $413.35.
Latest NEWS regarding these Stocks are depicted underneath:
Rock-Tenn Comapny (NYSE:RKT)
Rock-Tenn Corporation (RKT), and MeadWestvaco Corporation (MWV), declared that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to the pending business combination transaction between RockTenn and MWV has expired. The 30-day waiting period is required by the Federal Trade Commission and U.S. Department of Justice as part of the premerger notification program before such a combination transaction can close.
On Feb. 6, 2015, RockTenn and MWV filed the requisite notification and report forms under the HSR Act with the U.S. antitrust authorities. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the pending business combination transaction, which remains subject to other customary closing conditions, counting receipt of stockholder and shareholder approvals, as applicable, and other regulatory approvals.
Rock-Tenn Company manufactures and sells containerboard and paperboard products in the Unites States, Canada, Mexico, Chile, Argentina, and Puerto Rico. The company operates through four segments: Corrugated Packaging, Consumer Packaging, Merchandising Displays, and Recycling.
Teradyne Inc. (NYSE:TER)
Formerly on March 2, LitePoint, a wholly owned partner of Teradyne, Inc. (TER). LitePoint, an award-winning provider of wireless test solutions, declared new, advanced functionality for its cellular and connectivity products, designed to significantly raise manufacturing efficiency and throughput. LitePoint® Factory Efficiency tools are wireless test system options designed specifically to alert a test operator of issues before they influence the line, and save time and labor related to daily maintenance. As demonstrated in customer deployments, these features can enable a test station to deliver a larger volume of devices, resulting in getting more wireless devices to market faster while reducing capital costs and factory floor space.
The Factory Efficiency solution is showcased at Mobile World Congress in Barcelona, Spain, March 2 - 5 in the LitePoint Demo Lounge.
Teradyne, Inc. provides automatic test equipment worldwide. The corporation’s Semiconductor Test segment designs, manufactures, sells, and supports semiconductor test products and services for wafer level and device package testing in automotive, industrial, communications, consumer, computer and electronic game applications, and others.
General Growth Properties, Inc (NYSE:GGP)
General Growth Properties, Inc (GGP), will report financial and operational results for the first quarter 2015 after the close of business on Monday, April 27, 2015, and host a conference call for investors and other interested parties at 8:00 a.m. Central (9:00 a.m. Eastern) on Tuesday, April 28, 2015.
General Growth Properties, Inc is an equity real estate investment trust. The firm invests in the real estate markets of the United States. It engages in owning, managing, leasing, and redeveloping high-quality regional malls.
Biogen Idec Inc. (NASDAQ:BIIB)
Formerly on February 27, Biogen Idec Inc. (BIIB), and Swedish Orphan Biovitrum AB (publ) (Sobi) (SOBI.ST) recently declared positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of Alprolix® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under age 12 with severe haemophilia B. Alprolix was generally well tolerated and no inhibitors (neutralizing antibodies that may interfere with the activity of the therapy) were detected during the study. In this study, once-weekly prophylactic dosing with Alprolix resulted in low bleeding rates. Alprolix is the only approved hemophilia B therapy with prolonged circulation in the body.
The successful completion of Kids B-LONG supports applications for paediatric indications in several geographies and is an important step in seeking marketing authorisation for Alprolix in Europe. The European Medicines Agency requires the inclusion of paediatric study data in the initial marketing application for a new haemophilia therapy. Interim results of the Kids B-LONG study assisted support the U.S. approval of Alprolix for use in children.
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
